# aceRNA Technologies Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/acerna-technologies-co

- Industry: Biotechnology
- Headquarters: Kyoto-shi, Japan
- Website: www.acernatec.com
- Total disclosed funding: $2.5M
- Latest round: Series B (Dec 20, 2021)
- Investors on record: 3

## About

Established in 2018 and based in Kyoto, Japan, aceRNA Technologies Co., Ltd. operates as a biotechnology company that develops RNA design technology that can be used in regenerative medicine and gene therapy. In May 2024, aceRNA Technologies Co., Ltd. raised JPY 250 million in venture funding led by investors UTokyo Innovation Platform, Kyoto Capital Partners, DCI Partners Co., Ltd., and Mitsubishi UFJ Capital. The firm, as of August 2024, is led by its CEO, Fumihiro Sugawa.

The company focuses on RNA Switch technology, utilizing engineered micro RNAs (miRNAs) to precisely target and treat specific cells, minimizing side effects. Its flagship RNA Switch system enhances treatment accuracy for diseases with limited options, with potential uses in both mRNA-based and gene therapies, reducing unintended effects on non-target cells.

The company plans to utilize the May 2024 funding to continue the development of its RNA design technology.

## Funding rounds

- Series B, Dec 20, 2021, $2.5M — Mitsubishi UFJ Capital, Nitto Denko Corporation
- Seed, Nov 9, 2018 — Kyoto University Innovation Capital

## Investors

- Kyoto University Innovation Capital (https://capitalatlas.ai/funds/kyoto-university-innovation-capital) — Seed
- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series B
- Nitto Denko Corporation — Series B